Works matching AU Avigdor, Abraham

Results: 76
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT.

    Published in:
    2023
    By:
    • Timmerman, John;
    • Lavie, David;
    • Johnson, Nathalie;
    • Avigdor, Abraham;
    • Borchmann, Peter;
    • Andreadis, Charalambos;
    • Bazargan, Ali;
    • Gregory, Gareth;
    • Keane, Colm;
    • Tzoran, Inna;
    • Vucinic, Vladan;
    • Luigi Zinzani, Pier;
    • Marceau West, Rachel;
    • Pillai, Pallavi;
    • Marinello, Patricia;
    • Herrera, Alex F.
    Publication type:
    Abstract
    12

    P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA.

    Published in:
    2023
    By:
    • Johnson, Nathalie;
    • Lavie, David;
    • Borchmann, Peter;
    • Gregory, Gareth;
    • Herrera, Alex F.;
    • Minuk, Leonard;
    • Vucinic, Vladan;
    • Armand, Philippe;
    • Avigdor, Abraham;
    • Gasiorowski, Robin;
    • Herishanu, Yair;
    • Keane, Colm;
    • Kuruvilla, John;
    • Marceau West, Rachel;
    • Pillai, Pallavi;
    • Marinello, Patricia;
    • Timmerman, John
    Publication type:
    Abstract
    13
    14

    P061: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Anti–PD‐1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.

    Published in:
    HemaSphere, 2022, v. 6, p. 28, doi. 10.1097/01.HS9.0000890812.66186.e8
    By:
    • Borchmann, Peter;
    • Johnson, Nathalie A.;
    • Lavie, David;
    • Gregory, Gareth;
    • Herrera, Alex F.;
    • Minuk, Leonard;
    • Vucinic, Vladan;
    • Armand, Philippe;
    • Avigdor, Abraham;
    • Gasiorowski, Robin;
    • Herishanu, Yair;
    • Keane, Colm;
    • Kuruvilla, John;
    • Palcza, John;
    • Pillai, Pallavi;
    • Nahar, Akash;
    • Timmerman, John
    Publication type:
    Article
    15

    T058: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD‐1 Treatment.

    Published in:
    HemaSphere, 2022, v. 6, p. 27, doi. 10.1097/01.HS9.0000890800.36906.bb
    By:
    • Timmerman, John;
    • Lavie, David;
    • Johnson, Nathalie A.;
    • Avigdor, Abraham;
    • Borchmann, Peter;
    • Andreadis, Charalambos;
    • Bazargan, Ali;
    • Gregory, Gareth;
    • Keane, Colm;
    • Tzoran, Inna;
    • Vucinic, Vladan;
    • Zinzani, Pier Luigi;
    • Zhang, Hong;
    • Pillai, Pallavi;
    • Nahar, Akash;
    • Herrera, Alex F.
    Publication type:
    Article
    16
    17
    18
    19

    Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

    Published in:
    Leukemia & Lymphoma, 2021, v. 62, n. 1, p. 118, doi. 10.1080/10428194.2020.1824069
    By:
    • Segman, Yafit;
    • Ribakovsky, Elena;
    • Avigdor, Abraham;
    • Goldhecht, Yair;
    • Vainstein, Vladimir;
    • Goldschmidt, Neta;
    • Harlev, Shimrit;
    • Horwitz, Netanel;
    • Gutwein, Odit;
    • Gurion, Ronit;
    • Itchaki, Gilad;
    • Abadi, Uri;
    • Nemets, Anatoly;
    • Sofer, Orit;
    • Zektser, Miri;
    • Tadmor, Tamar;
    • Dally, Nagib;
    • Filanovsky, Kalman;
    • Leiba, Merav;
    • Sarid, Nadav
    Publication type:
    Article
    20

    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 13, p. 3188, doi. 10.1080/10428194.2020.1795159
    By:
    • Fraser, Graeme A.M.;
    • Chanan-Khan, Asher;
    • Demirkan, Fatih;
    • Santucci Silva, Rodrigo;
    • Grosicki, Sebastian;
    • Janssens, Ann;
    • Mayer, Jiri;
    • Bartlett, Nancy L.;
    • Dilhuydy, Marie-Sarah;
    • Loscertales, Javier;
    • Avigdor, Abraham;
    • Rule, Simon;
    • Samoilova, Olga;
    • Pavlovsky, Miguel A.;
    • Goy, Andre;
    • Mato, Anthony;
    • Hallek, Michael;
    • Salman, Mariya;
    • Tamegnon, Monelle;
    • Sun, Steven
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.

    Published in:
    Pharmaceutical Research, 2019, v. 36, n. 7, p. N.PAG, doi. 10.1007/s11095-019-2605-8
    By:
    • Lavezzi, Silvia Maria;
    • de Jong, Jan;
    • Neyens, Martine;
    • Cramer, Paula;
    • Demirkan, Fatih;
    • Fraser, Graeme;
    • Bartlett, Nancy;
    • Dilhuydy, Marie-Sarah;
    • Loscertales, Javier;
    • Avigdor, Abraham;
    • Rule, Simon;
    • Samoilova, Olga;
    • Goy, Andre;
    • Ganguly, Siddhartha;
    • Salman, Mariya;
    • Howes, Angela;
    • Mahler, Michelle;
    • De Nicolao, Giuseppe;
    • Poggesi, Italo
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.

    Published in:
    Expert Review of Anticancer Therapy, 2024, v. 24, n. 9, p. 893, doi. 10.1080/14737140.2024.2373888
    By:
    • Peterlin, Pierre;
    • Saada-Bouzid, Esma;
    • Moskovitz, Mor;
    • Pigneux, Arnaud;
    • Yuda, Junichiro;
    • Sinnollareddy, Mahipal;
    • Henner, William R.;
    • Chen, Diana;
    • Freise, Kevin J.;
    • Leibman, Rachel S.;
    • Avigdor, Abraham;
    • Shimizu, Toshio
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50